Therapeutic Response

Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Carboplatin in combination with Cemiplimab and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Libtayo (cemiplimab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.